Blank

Raltegravir pharmacokinetics

Common Questions and Answers about Raltegravir pharmacokinetics

isentress

Avatar f tn At day 22, i took raltegravir from the box but im not sure whether i drank the pill with the water or not. Normally, I remember the pills that I drank through glass of water but i cannot remember this time whether i drank this pill with glass of water or not but i counted pills and i concluded that their numbers are as expected. I searched couple of papers and i concluded not to double the dose in the case of i used that pill.
Avatar f tn //www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm309863.htm ___________________________ Here is another: The Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Volunteers on Stable Buprenorphine/Naloxone Maintenance Therapy Co-administration of telaprevir did not increase withdrawal symptom frequency and there were no serious adverse events reported during or after completion of telaprevir co-administration.
Avatar f tn combining emtricitabine and tenofovir from the NRTI class, and raltegravir, from the integrase inhibitor class. There ARE alternative drugs available and possibly in Thailand they use lamivudine in place of raltegravir. I am definitely NOT a chemist, so I can't tell you for sure if the combination you're taking is appropriate. You should discuss your concerns with the doctor who prescribed PEP or a pharmacist/chemist. I wish you the best.
Avatar n tn - Absorption, oral: time to peak concentration 7h - Elimination half-life = 12 h (It says also that in general it can be administered once daily because it has a 24 h effect.Why?) - Can you give another example to clarify it better please? - When it says divide in 2 doses , does it mean only in the morning and dinner? 3 doses (morning-lunch-dinner)? Thank you for taking the time to answer!!
Avatar n tn I started PEP 2 hrs later (truvada, norvir, raltegravir, and preszita), my initial results are negative. I do not know the viral load of the patient yet, i can only pray that it is low. I know odds are 0.3% but that doesnt settle my fears, i am young and want to live a happy healthy life with KIDS! DR. please tell me if you have honstly heard of any cases like mine that have converted. I am in awe and feel like my life is totally over and ruined.
Avatar n tn I am currently taking truvada and isentress (raltegravir) is this enough I couldn't get my prescription for dolutegravir filled...is this pep enough?
Avatar n tn m confused on the prescriptions given to me I have a 7 day dose of raltegravir and dolutegravir...thought it was supposed to be 28 days?
Avatar n tn I appreciate your blunt response. I was prescribed Truvada + raltegravir (PEP) but could not obtain raltegravir in Europe. To be fair, I called the US PEP hotline who told me that I could take Truvada as PEP as there are no studies that prove it’s ineffective, so I didn’t start it without advice from the US HIV experts. I agree my anxiety is an issue but I legitimately was seeking an answer.
Avatar f tn Anyways I rushed to the hospital and was put on PEP at a maximum of 3 hours post exposure (truvada and raltegravir). I have taken the pills without missing any doses. At 3 weeks post exposure the lymph nodes in my neck swelled up slightly and I felt a tiny bit feverish. Checking my temperature rectally though revealed it was always in the 37s. These strange symptoms lasted only 2 days...could this be ARS?
Avatar m tn I actually went to the clinic, got PEP (truvada 200mg and Raltegravir 400mg), also done hiv prick test which was negative. Dr was helpful and explained everything for me. He also said best thing is as u guys suggest, ask him test but also if he is clear 6 weeks back also, but that also depends on trust. On my side i don't wanna embarrass him as twice he told me not to worry.
Avatar n tn In the following day, I finally could find a very good hospital with a specialized area for HIV treatment, and the doctor was quite surprised that they had given me just a Truvada. She added a Isentress (raltegravir) to my Pep treatment. But I could realized that she was quite worried because I had had only Truvada in the begining of my treatment and in the very deadline edge.
Avatar f tn I am taking Truvada and Raltegravir. Yesterday, (3 days after exposure and 2 days on PEP) I had protected sex with a female partner (I, the insertive male) and when I ejaculated I am afraid some spilled off the base of the condom. If I began PEP 24 hours after possible exposure and had protected sex with someone else on Day 2 of PEP, could I have biologically put them at risk for HIV if by any chance the ejaculate spilled off the condom?
Avatar m tn I can't help out on the pharmacokinetics, but your reasoning is sound: it doesn't make sense to dose so that the drug runs out. I'd query Schering-Plough as well as your hepatologist, if I were you. Please give me a heads-up if you solve the riddle.
7510956 tn?1411671417 //www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm375286.
Avatar n tn I started PEP (Truvada and ISENTRESS which is Raltegravir Potassium Tablets) in 47 hours. I also saw some case about PEP with blood transfusion. A 12 years old girl had a blood transfusion with hiv blood, she took PEP( tenofovir, emtricitabine, ritonavir-boosted darunavir (subsequently changed to lopinavir) and raltegravir) after 24 hours and had these PEP for three months. This girl also has cssr5 dna which is a dna that hard to infect hiv.
Avatar m tn Hepatic Impairment In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].
Avatar f tn Folic acid supplementation in folate-deficient patients with epilepsy changes the pharmacokinetics of phenytoin, usually leading to lower serum phenytoin concentrations and possible seizure breakthrough..." It however says that initiation of Folic acid and phenytoin together is beneficial. Since you can't go back and start all over again, you can take a small dose. It has been observed that as los as 1mg dose can perturb phenytoin’s levels, You may take doses lower than 1mg/day.
863754 tn?1239144755 However, physiological changes resulting from smoking cessation may alter the pharmacokinetics or pharmacodynamics of insulin; dosage adjustments may be necessary.
Avatar m tn The Phase 1 trial was designed to characterize the safety profile of ARC-520 across a range of doses and evaluate pharmacokinetics. It is a single-center, randomized, double-blind, placebo-controlled, single dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers. All subjects have been dosed and received either placebo or ARC-520 in doses ranging from 0.01 mg/kg to 2 mg/kg.
Avatar f tn i believe in the pre-clinical trials with healthy volunteers, researchers used Carbon14 to gauge the half-life and paths of elimination during pharmacokinetics studies. it is a common practice. perhaps that is what you are thinking about?
Avatar n tn I started PEP 2 hrs later (truvada, norvir, raltegravir, and preszita), my initial results are negative. I do not know the viral load of the patient yet, i can only pray that it is low. I know odds are 0.3% but that doesnt settle my fears, i am young and want to live a happy healthy life with KIDS! DR. please tell me if you have honstly heard of any cases like mine that have converted. I am in awe and feel like my life is totally over and ruined.
29837 tn?1414534648 The pharmacokinetics of ledipasvir were studied with a single dose of 90 mg ledipasvir in HCV negative subjects with severe hepatic impairment (Child-Pugh Class C). Ledipasvir plasma exposure (AUC0-inf) was similar in subjects with severe hepatic impairment and control subjects with normal hepatic function. Population pharmacokinetics analysis in HCV-infected subjects indicated that cirrhosis had no clinically relevant effect on the exposure of ledipasvir [see Use in Specific Populations (8.
808353 tn?1238293321 The combination of two potent direct-acting antivirals (DAAs), targeting two distinct viral enzymes, may offer advantages over single DAA strategies by enhancing potency, reducing the emergence of drug resistance, and possibly eliminating the need for PEG-IFN +/- ribavirin. The combination of R7128/R7227 offers the potential for a highly potent regimen with a high genetic barrier to resistance. Methods: INFORM-1 is a randomized, double-blind, ascending dose Phase I trial.